HCPCS Code J0610: Calcium gluconate injection, billing, and J0612 crosswalk

Key takeaways

HCPCS Code J0610 described injection of calcium gluconate (Fresenius Kabi brand), per 10 ml, and was deleted effective April 1, 2023.

The successor code is J0612 (injection, calcium gluconate, not otherwise specified, 10 mg). Claims submitted with J0610 after April 1, 2023 are automatically rejected.

J0612 bills per 10 mg, not per 10 mL. A standard 10 mL vial of 10% calcium gluconate holds 1,000 mg, or 100 units.

Practice management software like Pabau captures administered volume and clinical indication in the patient record, giving billers the data to calculate correct J0612 units.

HCPCS Code J0610 was a HCPCS Level II J-code for an injection of calcium gluconate (Fresenius Kabi brand), billed per 10 ml. CMS deleted it effective April 1, 2023, and claims that still show J0610 are rejected automatically. The bigger risk is the successor code, J0612, which bills by milligram instead of milliliter.

Clinical documentation tools like Pabau capture the administered volume and clinical indication in the patient record, giving billers the data to convert to units correctly. This guide covers what billers and practice managers need to code calcium gluconate injections correctly today.

What is HCPCS Code J0610?

HCPCS Code J0610 was a HCPCS Level II J-code describing an injection of calcium gluconate manufactured by Fresenius Kabi, billed per 10 ml. J-codes are used under Medicare Part B and Medicaid to bill for drugs administered in outpatient, physician office, and ambulatory surgical center (ASC) settings.

The code was brand-specific from its inception. That specificity matters: J0610 applied only to the Fresenius Kabi formulation of calcium gluconate injection. Providers administering a different manufacturer’s product were already expected to use an alternate code, most commonly J0612 or J3490 (unclassified drug).

HCPCS Code J0610 was deleted effective April 1, 2023, as part of the CMS quarterly HCPCS update. Claims submitted with J0610 for dates of service on or after April 1, 2023 are rejected by Medicare and most Medicaid programs.

J0610 code details at a glance

The table below summarises the key code attributes for HCPCS Code J0610 as it existed before deletion.

Note: the successor code J0612 does not carry over this per 10 mL billing unit. J0612 bills by weight instead, so the conversion below is essential before you submit a claim.

Is HCPCS Code J0610 still active? Understanding the April 2023 deletion

No. HCPCS Code J0610 is not active. The Centers for Medicare and Medicaid Services (CMS) deleted the code effective April 1, 2023, as part of the quarterly HCPCS Level II update cycle.

The CGS Medicare Administrative Contractor (Jurisdiction C) published explicit billing instructions on the change. Claims submitted with J0610 for service dates on or after that date will be rejected.

Why was J0610 deleted? CMS periodically rationalises brand-specific J-codes when a drug becomes widely available across multiple manufacturers. Tying reimbursement to a single brand’s code creates administrative complexity without clinical benefit. The April 2023 update consolidated calcium gluconate billing under the non-brand-specific successor J0612.

• For dates of service before April 1, 2023: J0610 was valid. Corrected or resubmitted claims for those earlier dates may still use J0610 if the original encounter predates the deletion.
• For dates of service on or after April 1, 2023: J0612 is the correct code. Using J0610 generates an automatic rejection.
• For Medicaid programs: State Medicaid programs generally follow the CMS HCPCS update schedule, but confirm with your specific state MAC or managed Medicaid plan.

J0610 vs J0612: Crosswalk and successor code

The crosswalk from J0610 to J0612 is not a straight one-to-one swap. J0612 is also non-brand-specific, covering IV therapy and infusion settings where calcium gluconate from any manufacturer is administered. But its billing unit changed from volume to weight, and getting that difference wrong is the single most consequential mistake in this crosswalk.

The billing unit is not identical, and this is the detail every biller must get right. J0610 billed per 10 mL of solution. J0612 bills per 10 mg of calcium gluconate. That is a mass-based unit, not a volume-based one.

Converting between the two means multiplying volume by concentration, not carrying the old unit count forward. A standard 10% calcium gluconate solution contains 100 mg per mL. A 10 mL single-dose vial therefore holds 1,000 mg, or 100 units of J0612. That same vial was 1 unit under J0610.

Apply that conversion consistently. A 20 mL dose is 2,000 mg, or 200 units, not 2. A 30 mL infusion is 3,000 mg, or 300 units, not 3. Reading J0612 as a per-10-mL code, the way J0610 worked, underbills a claim by a factor of 100.

That miscount changes what the claim pays. At the ASP payment limit, 100 units of J0612 price out to roughly $2.80 per vial, compared with $0.028 under the mistaken 1-unit reading. CMS also flags J0612 as a single-dose container, so unused drug from a partial vial needs a JW or JZ wastage modifier.

Clinical indications for calcium gluconate injection

Understanding why calcium gluconate is administered helps billers confirm medical necessity and select the correct supporting ICD-10 diagnosis code. Practices running IV therapy programs or infusion centers encounter these clinical scenarios most frequently. Functional medicine practices offering IV nutrient therapy administer calcium gluconate for many of the same indications.

• Hypocalcemia (low serum calcium): The most common indication. Causes include hypoparathyroidism, vitamin D deficiency, chronic kidney disease, and post-surgical calcium loss. Calcium gluconate IV is preferred over calcium chloride in most outpatient settings because it causes less vascular irritation on extravasation.
• Hyperkalemia with cardiac toxicity: IV calcium gluconate stabilises the cardiac membrane in emergency hyperkalemia management. It does not lower serum potassium but protects the myocardium from arrhythmia while other treatments take effect.
• Magnesium toxicity: Calcium gluconate is the antidote for severe hypermagnesemia, reversing neuromuscular and cardiovascular effects. This is relevant in obstetric settings where magnesium sulfate is used for preeclampsia management.
• Hydrofluoric acid (HF) exposure: Topical or systemic HF poisoning causes severe hypocalcemia and potentially fatal arrhythmias. IV calcium gluconate is a critical intervention. Documentation of HF exposure as a toxicological emergency is essential for claim support.
• Citrate toxicity during massive transfusion: Large-volume blood product administration depletes ionised calcium. Calcium gluconate is administered to correct transfusion-associated hypocalcemia in trauma and surgical settings.

ICD-10 diagnosis codes commonly paired with J0610 / J0612

Pairing the drug code with the correct ICD-10 diagnosis is what establishes medical necessity for the claim. The CMS Physician Fee Schedule and MAC local coverage determinations require that the submitted diagnosis code supports the clinical rationale for IV calcium gluconate administration.

Note: ICD-10 code E83.51 (hypocalcemia) is more specific than the older E83.5 grouping referenced in some older resources. Use the most specific code supported by your clinical documentation. Guides on IV therapy complications consistently emphasize documenting the specific calcium deficiency type rather than defaulting to unspecified codes.

Medicare reimbursement for calcium gluconate injections

Medicare reimburses J-code drug injections under the Average Sales Price (ASP) methodology. The payment rate for J0612 (and formerly J0610) is calculated as ASP plus 6% for physician office and outpatient settings, updated quarterly by CMS.

ASP pricing changes every quarter. Never cite a specific dollar amount for J0612 reimbursement without referencing the current HCPCS fee schedule data for that quarter.

Setting matters significantly for reimbursement. IV vitamin therapy administration and calcium gluconate infusions may occur across several care settings, each with different payment rules:

• Physician office: Medicare Part B pays ASP + 6% for the drug. Bill the drug administration separately under CPT code 96365 for initial infusion.
• Hospital outpatient department (HOPD): Drug reimbursement is packaged under the APC (Ambulatory Payment Classification) system. Separate drug payment may not apply for low-cost drugs.
• Ambulatory surgical center (ASC): ASC drug payment rules differ from HOPD. Some J-codes are separately reimbursable in ASCs; confirm against the current CMS ASC drug payment list.

Documentation requirements for billing calcium gluconate injections

Medical necessity documentation is not optional. CMS requires it for claim acceptance on J-code drug injections, and auditors specifically look for it during post-payment reviews. Digital intake and clinical forms make it easier to capture the required elements at the point of care. That beats reconstructing them from memory during an audit.

Required documentation elements for calcium gluconate injection billing:

• Drug name: Calcium gluconate (generic name is acceptable; Fresenius Kabi specificity was required under J0610 but is no longer necessary under J0612)
• Dosage and volume: Total milliliters administered, converted to milligrams using the product’s concentration, since J0612 bills 1 unit per 10 mg
• Route of administration: Intravenous (IV), with notation of infusion method (peripheral vs central line where relevant)
• Clinical indication: The diagnosis justifying the administration, mapped to the ICD-10 code on the claim
• Prescribing or ordering clinician: Name, credentials, and NPI of the practitioner who ordered the drug
• Date and time of administration: Supports the claim date and drug administration CPT code billing
• Lot number and expiration date: Required for controlled documentation in outpatient infusion settings

Common billing errors and how to avoid them

This is where J0610 claims most often go wrong. These error patterns are the most common audit triggers for calcium gluconate injection billing. IV therapy clinic operators setting up billing workflows for the first time are especially vulnerable to these mistakes.

• Still billing J0610 after April 1, 2023: The most common and most preventable error. Update your CDM and any billing templates immediately. There is no grace period for deleted HCPCS codes under Medicare.
• Unit miscounting (10 mg, not 10 mL): J0612 bills 1 unit per 10 mg of calcium gluconate, not per 10 mL and not per vial. A standard 10 mL vial (100 mg/mL) is 1,000 mg, or 100 units. A 20 mL dose is 200 units. A 30 mL infusion is 300 units. Billing 1 unit per 10 mL vial, the way J0610 worked, underbills the claim by a factor of 100.
• Mismatched ICD-10 diagnosis code: Submitting J0612 with a diagnosis code that does not support medical necessity for calcium gluconate (for example, a musculoskeletal code with no documented hypocalcemia) generates a medical necessity denial.
• Missing drug administration CPT code: The J-code covers only the drug. Bill the infusion service separately using 96365 for the initial hour, with additional-hour codes for longer infusions. Billing the drug code without the administration code leaves revenue uncaptured.
• Using J3490 (unclassified drug) when J0612 applies: J3490 is for drugs without an assigned J-code. Since J0612 is the correct active code for calcium gluconate, billing J3490 invites manual review, delays payment, and points to a coding process that needs a closer look.

How Pabau supports accurate calcium gluconate documentation

Many infusion practices document the administered drug and volume on paper or in a separate note. That information then gets re-entered into the billing system when the claim goes out. Details can drift between the clinical note and the claim in that step. That is where mismatches between the diagnosis code, the drug volume, and the HCPCS units start.

Practice management software like Pabau keeps the clinical note and the patient record in the same system. The drug name, volume, route, and clinical indication get captured once, at the point of care. Digital forms and treatment notes record the administered dose alongside the diagnosis, giving billers one auditable source to calculate J0612 units correctly.

Key documentation capabilities that support accurate HCPCS J-code billing:

• Treatment notes and clinical records that capture the administered drug name, volume, route, and clinical indication in the patient record at the point of care
• Digital clinical forms that capture ICD-10 diagnosis and medical necessity information before the appointment ends
• Integrated invoicing that pulls treatment and drug details directly from the patient record, reducing manual re-entry when a bill goes out
• Multi-location visibility for practice managers overseeing more than one infusion site

For clinics exploring IV therapy intake form best practices, Pabau’s digital forms can be configured to collect the data elements billers need. That supports accurate J0612 coding. Read more about IV hydration business requirements to understand the broader regulatory context for infusion clinics.

Capture clean documentation for every infusion

Pabau's digital forms and treatment notes capture the administered volume, route, and clinical indication at the point of care. That gives billers the documentation to support accurate coding.

Book a demo

Conclusion

Getting this crosswalk wrong costs more than a single rejected claim. A biller who miscounts J0612 units by treating it like the old per-10-mL code underbills every calcium gluconate claim by a factor of 100. The fix is procedural, not clinical. Update the charge description master, confirm the ICD-10 pairing, and convert volume to milligrams before the claim goes out.

Practice management software like Pabau keeps the drug name, volume, route, and diagnosis together in one record. That lets billers convert units correctly the first time instead of reconstructing the claim from memory. Book a demo to see how Pabau supports clean clinical documentation for infusion practices.

Continue your research

Billing for an infusion catheter alongside the drug code? C1751 covers the catheter billing, the modifiers payers expect, and the documentation that supports the claim.

Running home infusion services instead of an office visit? S9379 covers billing for home infusion therapy, including per diem rates and required documentation.

Managing a multi-location IV therapy operation? IV therapy marketing strategies covers how to scale patient acquisition alongside compliant clinical operations.

Frequently asked questions